Transcode Therapeutics, INC Schedule 13D activist filings

DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. have converted substantial preferred stock into common shares, increasing their beneficial ownership.

DEFJ, LLC and CK Life Sciences Int'l. (Holdings) Inc. report a conversion of Series B Preferred Stock into common stock, bringing their beneficial ownership to 9.9% of TransCode Therapeutics.

DEFJ LLC has submitted a conversion notice for Series B Preferred Stock in TransCode Therapeutics, Inc., contingent on stockholder approval of key proposals.

TransCode Therapeutics, Inc. has amended its Contingent Value Rights Agreement and the terms of its Series A and B Preferred Stock, impacting conversion limitations and delisting provisions.

TransCode Therapeutics, Inc. completed the acquisition of ABCJ, LLC from DEFJ, LLC and secured a $25 million private placement, issuing common and preferred stock, and contingent value rights.

Investor Thomas J. Tracy has disclosed a 5.0% beneficial ownership stake in Transcode Therapeutics, Inc., signaling an intent to engage with management and the Board on strategies to enhance shareholder value, including commercialization and fundraising approaches.